1. Academic Validation
  2. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor

Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor

  • Cell Death Dis. 2021 Jul 14;12(7):699. doi: 10.1038/s41419-021-03994-0.
Tom Delanghe 1 2 Jon Huyghe 1 2 Seungheon Lee 3 Dario Priem 1 2 Samya Van Coillie 1 2 Barbara Gilbert 1 2 Sze Men Choi 1 2 Peter Vandenabeele 1 2 Alexei Degterev 4 Gregory D Cuny 3 Yves Dondelinger 1 2 Mathieu J M Bertrand 5 6
Affiliations

Affiliations

  • 1 VIB Center for Inflammation Research, 9052, Ghent, Belgium.
  • 2 Department of Biomedical Molecular Biology, Ghent University, 9052, Ghent, Belgium.
  • 3 Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA.
  • 4 Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA, 02111, USA.
  • 5 VIB Center for Inflammation Research, 9052, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.
  • 6 Department of Biomedical Molecular Biology, Ghent University, 9052, Ghent, Belgium. mathieu.bertrand@irc.vib-ugent.be.
Abstract

Butylate hydroxyanisole (BHA) is a synthetic phenol that is widely utilized as a preservative by the food and cosmetic industries. The antioxidant properties of BHA are also frequently used by scientists to claim the implication of Reactive Oxygen Species (ROS) in various cellular processes, including cell death. We report on the surprising finding that BHA functions as a direct inhibitor of RIPK1, a major signaling hub downstream of several immune receptors. Our in silico analysis predicts binding of 3-BHA, but not 2-BHA, to RIPK1 in an inactive DLG-out/Glu-out conformation, similar to the binding of the type III inhibitor Nec-1s to RIPK1. This predicted superior inhibitory capacity of 3-BHA over 2-BHA was confirmed in cells and using in vitro kinase assays. We demonstrate that the reported protective effect of BHA against tumor necrosis factor (TNF)-induced necroptotic death does not originate from ROS scavenging but instead from direct RIPK1 enzymatic inhibition, a finding that most probably extends to other reported effects of BHA. Accordingly, we show that BHA not only protects cells against RIPK1-mediated Necroptosis but also against RIPK1 kinase-dependent Apoptosis. We found that BHA treatment completely inhibits basal and induced RIPK1 enzymatic activity in cells, monitored at the level of TNFR1 complex I under apoptotic conditions or in the cytosol under Necroptosis. Finally, we show that oral administration of BHA protects mice from RIPK1 kinase-dependent lethality caused by TNF injection, a model of systemic inflammatory response syndrome. In conclusion, our results demonstrate that BHA can no longer be used as a strict antioxidant and that new functions of RIPK1 may emerge from previously reported effects of BHA.

Figures
Products